Cantor Fitzgerald Lifts PT on Innoviva, Inc. (INVA) to $32 from $31 - Here's Why

Innoviva, Inc. (NASDAQ:INVA) is one of the best cheap biotech stocks to buy now. Cantor Fitzgerald lifted the price target on Innoviva, Inc. (NASDAQ:INVA) to $32 from $31 on February 26, maintaining an Overweight rating on the shares. The firm told investors in a research note that the fiscal Q4 revenue of $114.6M surpassed expectations, driven primarily by continued XacDuro inventory builds in China, potentially boosting royalties and milestones in 2026+.

The rating update came after Innoviva, Inc. (NASDAQ:INVA) reported its fiscal Q4 and full year 2025 results on February 25, stating that the durable royalties portfolio generated $58.4 million in revenue for fiscal Q4 and $250.3 million for the full year. Management further reported that IST attained U.S. net product sales of $33.9 million for fiscal Q4 and $119.2 million for the full year, reflecting a 47% year-over-year growth. In addition, the IST product portfolio was strengthened with the U.S. FDA approval of NUZOLVENCE®, which is a first-in-class treatment for uncomplicated urogenital gonorrhea. Innoviva, Inc. (NASDAQ:INVA) also initiated a $125 million share repurchase program in fiscal Q4.

Innoviva, Inc. (NASDAQ:INVA) is involved in the development, commercialization, and financial management of biopharmaceuticals.

While we acknowledge the potential of INVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.